- | Arrowhead Pharmaceuticals
Arrowhead shares soar on liver disease data from four patients
Arrowhead is one of the leading companies researching RNA interference, a Nobel Prize-winning technology that has been aimed at an array of chronic and genetic diseases.
- | Valneva
Valneva to create ‘major UK vaccine facility’ as part of UK COVID-19 vaccine deal
Valneva SE has announced a vaccine partnership with the UK Government for its inactivated COVID-19 vaccine, covering up to 190 million doses.
- | Vaxart
Vaxart’s oral COVID-19 tablet vaccine to enter clinical trials
Vaxart will start a Phase 1 clinical trial for its oral COVID-19 vaccine candidate, having received Investigational New Drug (IND) clearance.
- | Valneva
VLA15 May be the First Vaccine Against Lyme Disease
Valneva, a France-based biotech company, is currently developing a drug that has the potential to treat Lyme disease. Called VLA15, the drug is in phase two of trials and the company is already planning for phase three.
- | Orasis Pharmaceuticals
Orasis Pharmaceuticals snags $30M to see its presbyopia treatment through to PhIII
Orasis Pharmaceuticals is one of several biotechs developing miotic-based eye drops as a potential alternative to reading glasses — one drop, and no more squinting at text messages. With the help of a $30 million Series C, the Israel-based company has its sights set on Phase III.
- | Recce Pharmaceuticals
Two drug candidates show promise against COVID-19 in organoid system
An Australian-based biotech company has announced positive, dose-dependent reductions against SARS-CoV-2 infection, the virus that causes COVID-19, following treatment with two anti-infective drug candidates, RECCE® 327 and RECCE® 529 (R327 and R529). Recce Pharmaceuticals, which developed the candidates, says it will be advancing the compounds to in vivo studies in ferrets in a US study.
- | Celyad Oncology
Phase 1 Trial Featuring First shRNA-Edited CAR-T Therapy to Begin
The allogeneic therapy, CYAD-211 from Celyad Oncology, is unique insofar that it uses short-hairpin RNA (shRNA) editing to knock down the CD37 component of the T-cell receptor (TCR). It is a first-in-class CAR-T candidate, meaning it would represent the first CAR-T therapy that uses this gene-editing approach.
- | DURECT
‘Promising’ treatment for alcoholic hepatitis in development
Flamm said one drug currently in development, DUR-928 (Durect), has demonstrated good tolerability in previous research. He said that research presented at The Digital International Liver Congress explored pharmacokinetics of the drug and identified appropriate dosing levels in a phase 2b trial.
